Colony formation of soft tissue sarcoma cells is inhibited by lipid- mediated antisense oligodeoxynucleotides targeting the human mdm2 oncogene

Cancer Letters

Volumn 149, Issue 1-2, 2000, Pages 181-188

  Meye, Axel ^a   Würl, Peter ^b   Bache, Matthias ^a   Bartel, Frank ^a   Grünbaum, Ulrich ^a   Mansa ard, Jasadee ^a   Schmidt, Hannelore ^a   Taubert, Helge ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Antisense phosphorothioates; Cell cycle distribution; Liposomal transfection; mdm2 Oncogene; Soft tissue sarcoma cell line; Western blot analysis

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; LIPOFECTAMINE; PROTEIN MDM2;

APOPTOSIS; ARTICLE; CELL CYCLE; CLONOGENESIS; COLONY FORMATION; CONTROLLED STUDY; GENE AMPLIFICATION; GENE MUTATION; GENE OVEREXPRESSION; GENE TARGETING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; ONCOGENE; PRIORITY JOURNAL; SARCOMA CELL; SOFT TISSUE SARCOMA;

CELL DIVISION; DRUG CARRIERS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE THERAPY; HUMANS; LIPOSOMES; NEOPLASM PROTEINS; NUCLEAR PROTEINS; OLIGONUCLEOTIDES, ANTISENSE; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; SARCOMA; TUMOR CELLS, CULTURED; TUMOR STEM CELLS;

EID: 0343314893     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(99)00356-0     Document Type: Article

References (28)

1. Pollock R.E., Karnell L.H., Menck H.R., Winchester D.P. The national cancer data base report on soft tissue sarcoma. Cancer. 78:1996;2247-2257.
2. Enzinger F.M., Weiss G.M. Soft Tissue Tumors, 2nd Edition. 1995;Mosby, St. Louis, MO.
3. Cordon-Cardo C., Latres E., Drobnjak M., Oliva M., Pollack D., Woodruff J.M., Marechal V., Chen J., Brennan M-F., Levine A. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res. 54:1994;794-799.
4. Würl P., Meye A., Schmidt H., Lautenschläger C., Kalthoff H., Rath F.-W., Taubert H. High prognostic significance of Mdm2/p53 co-overexpression in soft tissue sarcomas of the extremities. Oncogene. 16:1998;1183-1185.
5. Chen L., Agrawal S., Zhou W., Thang R., Chen J. Synergistic activation of p53 by inhibition of MDM2 expression and DNA damage. Proc. Natl. Acad. Sci. USA. 95:1998;195-200.
6. Freedman D.A., Wu L., Levine A.J. Functions of the MDM2 oncoprotein. Cell. Mol. Life Sci. 55:1999;96-107.
7. Wu X., Bayle H., Olson D., Levine A.J. The p53-mdm2 autoregularory feedback loop. Genes Dev. 7:1993;1126-1132.
8. Piette J., Neel H., Marechal V. Mdm2: keeping p53 under control. Oncogene. 15:1997;1001-1010.
9. Milas M., Yu D., Pollock R.E. Advances in the understanding of human soft tissue sarcomas: molecular biology and therapeutic strategies. Oncol. Reports. 5:1997;1275-1279.
10. Taubert H., Meye A., Würl P. Sarcomas and p53 mutations. Mol. Med. 4:1998;365-372.
11. Würl P., Meye A., Berger D., Bache M., Lautenschläger C., Schmidt H., Kalthoff H., Dralle H., Rath F.-W., Taubert H. Prognostic relevance of C-terminal MDM2 detection is enhanced by positivity in soft tissue sarcomas. Diagn. Mol. Pathol. 6:1997;249-254.
12. Meye A., Bache M., Hinze R., Schmidt H., Würl P., Holzhausen H.-J., Rath F.-W., Taubert H. Molecular characterization and liposomal transfection of a p53-mutated cell line established from a poorly undifferentiated leiomyosarcoma. Int. J. Oncol. 13:1998;241-248.
13. Taubert H., Schmidt H., Würl P., Hinze R., Meye A., Bache M., Berger D., Holzhausen H.-J., Rath F.-W. Morphological and molecular characterization of an undifferentiated soft tissue sarcoma cell line and derivative clones. Int. J. Oncol. 11:1997;521-526.
14. Kondo S., Barnett G.H., Hara H., Morimura T., Takeuchi J. MDM2 protein confers the resistance of a human glioblastoma cell line to cisplatin-induced apoptosis. Oncogene. 10:1995;2001-2006.
15. Bache M., Dunst J., Würl P., Fröde D., Meye A., Schmidt H., Rath F.-W., Taubert H. Analysis of G2/M arrest and apoptosis after irradiation with X-rays in five human sarcoma cell lines. Anticancer Res. 19:1999;1827-1832.
16. Olson D.C., Marechal V., Momand J., Chen J., Romocki C., Levine A.J. Identification and characterisation of multiple mdm2 proteins and mdm2-p53 protein complexes. Oncogene. 8:1993;2353-2360.
17. Teoh G., Urashima M., Ogata A., Chauhan D., DeCaprio J.A., Treon S.P., Schlossmann R.L., Anderson K.C. MDM2 protein overexpression promotes proliferation and survival of multiple myeloma cells. Blood. 90:1997;1982-1992.
18. Weiss B. Antisense Oligodeoxynucleotides and Antisense RNA. 1997;CRC Press, Boca Raton, FL.
19. Stewart N., Hicks G.G., Paraskevas F., Mowat M. Evidence for a cell cycle block at G2M by p53. Oncogene. 12:1996;237-245.
20. Wahl A.F., Donaldson K.L., Fairchild C., Lee F.Y.F., Foster S.A., Demers G.W., Galloway D.A. Loss of normal p53 function confers sensitization to taxol by increasing G2M arrest and apoptosis. Nat. Med. 2:1996;72-79.
21. Brown D.R., Thomas C.A., Deb S.P. The human oncoprotein MDM2 arrests the cell cycle: elimination of ist cell-cycle-inhibitory function induces tumorigenesis. EMBO J. 17:1998;2513-2525.
22. Chen L., Lu W., Agrawal S., Zhou W., Zhang R., Chen J. Ubiquitous induction of p53 in tumor cells by antisense inhibition of mdm2 expression. Mol. Med. 5:1999;21-34.
23. Sigalas I., Calvert A.H., Anderson J.J., Neal D.E., Lunec J. Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: transforming ability and frequent detection in human cancer. Nat. Med. 2:1996;912-917.
24. Lasic D.D. Liposomes in Gene Delivery. 1997;CRC Press, Boca Raton, FL.
25. Arriola E.L., Lopez A.R., Chresta C.M. Differential regulation of p21waf-1/cip-1 and Mdm2 by etoposide: etoposide inhibits the p53-Mdm2 autoregulatory feedback loop. Oncogene. 18:1999;1081-1091.
26. Tortora G., Caputo R., Bianco R., Damiano V., Pomatico G., Bianco A.R., Agrawal S., Ciardiello F. Antitumor activity of a novel MBO antisense MDM2 and cooperative activity with other antitumor agents in vitro and in vivo. Proc. Am. Assoc. Cancer Res. 40:1999;730. (abstract 4820).
27. Zhang R., Zeng X.F., Oliver P., Chen J., Agrawal S. Inhibition MDM2 oncogene expression as a new approach to cancer therapy: in vitro and in vivo studies. Proc. Am. Assoc. Cancer. Res. 40:1999;484. (abstract 3197).
28. Wang H., Zheng X.F., Oliver P., Le L.P., Chen J.D., Zhou W.Q., Agrawal S., Zheng R.W. MDM2 oncogene as a target for cancer therapy: an antisense approach. Int. J. Oncol. 15:1999;653-660.